DOI work
Fetched
Post
crossref
Chui Mae Wong, Charmain Samantha Tan, Natasha Riard, Yeleswarapu Sita Padmini, Lourdes Mary Daniel, Arun Prasath, Ah. Moy Tan, Thiam Chye Tan, et al.
(2024).
Autologous umbilical cord blood infusion for the treatment of autism in young children: A within‐subjects open label study on safety (assessed via caregiver report) and efficacy.
Autism Research, 17(8), 1721-1734.
Wiley.
- Publication date
-
29 Jun 2024
- Identifier
-
10.1002/aur.3187
- Authors
-
Chui Mae Wong,
Charmain Samantha Tan,
Natasha Riard,
Yeleswarapu Sita Padmini,
Lourdes Mary Daniel,
Arun Prasath,
Ah. Moy Tan,
Thiam Chye Tan,
Rehena Sultana,
Joyce Ching Mei Lam
- Source
- Autism Research
- Details
- 17(8), 1721-1734
- Reference type
- article
- Publisher
- Wiley
- Metadata source
- crossref
Abstract
Abstract This study aimed to document the safety and efficacy of a single infusion of autologous umbilical cord blood (UCB) in 20 autistic children aged 24–72 months. A pre‐post treatment within‐subjects open label design was used. At T = 0, 6, 12, and 18 months, participants underwent detailed and structured safety evaluations (via caregiver report), Vineland Adaptive Behavior Scale (Vineland‐3), Stanford Binet Intelligence Scale (SB‐5), Expressive One‐Word Picture Vocabulary Test, Brief Observation of Social Communication Change (BOSCC), Pervasive Developmental Disorder‐Behavior Inventory, Repetitive Behavior Scale‐Revised, Sensory Experience Questionnaire (SEQ‐2.1), Child Behavior Checklist, Clinical Global Impression‐Severity and Improvement (CGI‐I) Scales, and eye‐gaze tracking. UCB infusion was conducted at T = 6 months, hence, 0–6 months was the control period, and 6–18 months the follow‐up period. Of 20 children recruited, 19 completed the study and 1 was withdrawn due to UCB not meeting quality control criteria for infusion. There were 15 males and 4 females with an overall mean (SD) age of 4.15 (0.62) years. Mean (SD) cell dose administered was 38.16 (9.82) million cells/kg. None suffered serious adverse events although there were mild behavioral side effects and one unit grew coagulase negative staphylococcus from a post‐thaw sample. There were no significant differences in Vineland‐3, SB‐5, BOSCC, and SEQ‐2.1 scores at T = 12 and T = 18 months. Twelve participants had T = 18 CGI‐I scores of 2–3 (minimally to much improved), seven participants had scores of 4 (no change). Autologous UCB infusion in autistic children is generally safe but not without risks, including that of infection. In this within‐subjects study, some children showed global symptom improvements while others showed no change. Stem cell therapies for autism should only be conducted under strict clinical trial conditions with clear risk discussions.
Study authors in this cited reference